Getting started in 3D - Setting up your lab and reviewing common pitfalls of researchers new to 3D

As we develop new methods to create more biologically relevant models for research in understanding disease etiology and innovating new treatment options, one of the most requested areas for educational materials is 3D cell models such as organoid and spheroid systems. Thermo Fisher Scientific is proud to present our webinar series on 3D culture & analysis, and more importantly, how you can get started, how to monitor and analyze 3D models and what to do with these once you have successfully cultured your organoid or spheroid model of interest. In this series we will specifically cover the following areas and after taking part in the presentations, hopefully you will be better equipped to answer the basic questions and feel enabled to get started using 3D culture systems.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Data Science Applications in Laboratory Medicine

The practice of medicine is changing rapidly to include the introduction of automated and algorithmic solutions to clinical and operational challenges.
Watch Now

How effective is it for pharma pricing & forecasting? Some evidence-based answers

Artificial intelligence (AI) - “getting computers to do things that normally require a human mind” - is routinely being put to good use when making pharma clinical development decisions.
Watch Now

Studies of Mosquito Immunology and Plasmodium Virulence Using Imaging Flow Cytometry

Millipore Sigma

The classification of mosquito blood cells is controversial, complicated by the small size and number of cells one can obtain per mosquito, by the autofluorescent debris found in hemolymph, and the tendency of phagocytes to take up this autofluorescent debris. Much of the classification has been performed morphologically on cytospins of isolated cells. Imaging flow cytometry yields simultaneously acquired bright field, scatter, and fluorescent images of cells in suspension, enabling better resolution of rare cells from debris.
Watch Now

Gene Therapy for Rare Diseases: Considerations for Both Clinical and Post-Marketing Studies

Quanticate

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. Scientific advances such as the CRISPR/Cas9 genome-engineering system have simplified the pharmaceutical and biotech industry’s ability to develop gene therapies, especially for single gene mutation disorders. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.
Watch Now

Spotlight

resources